Key points are not available for this paper at this time.
These results offer preclinical evidence for myricetin as a potential chemopreventive and therapeutic agent for precision medicine tailored to prostate cancer patients characterized by concomitant elevated expression of PIM1 and CXCR4.
Ye et al. (Mon,) studied this question.